COSCIENS Biopharma Net Profit Margin 2010-2024 | CSCI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

COSCIENS Biopharma net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

COSCIENS Biopharma net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$180.1B
Regeneron Pharmaceuticals (REGN)	$127.1B
Vertex Pharmaceuticals (VRTX)	$126.3B
Gilead Sciences (GILD)	$103.5B
Bristol Myers Squibb (BMY)	$101.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$90.3B
Alnylam Pharmaceuticals (ALNY)	$34.7B
Argenex SE (ARGX)	$32.2B
BioNTech SE (BNTX)	$29.4B
Biogen (BIIB)	$29.1B
Moderna (MRNA)	$26.6B
Illumina (ILMN)	$20.6B
BeiGene (BGNE)	$19.1B
Genmab (GMAB)	$17.6B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$12.8B
Incyte (INCY)	$12.8B
Vaxcyte (PCVX)	$12.8B
Insmed (INSM)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.6B
Legend Biotech (LEGN)	$9.4B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.1B
Halozyme Therapeutics (HALO)	$8B
Intra-Cellular Therapies (ITCI)	$8B
Repligen (RGEN)	$7.8B